Drug platforms
A method to rapidly mobilize donor HSCs from the bone marrow to the blood by antagonizing CXCR4 and agonizing CXCR2 could be useful for HSCTs. In mice, subcutaneous injection of the CXCR4 antagonist Mozobil plerixafor and a CXCR2 agonist tool compound mobilized HSCs from the bone marrow to the blood within 15 minutes, whereas a conventional granulocyte colony-stimulating factor (G-CSF; CSF3)-based protocol did so after four days. In a mouse model of HSCT, transplantation of peripheral blood mononuclear cells (PBMCs) from healthy donors pretreated with the CXCR2 agonist plus Mozobil increased donor cell engraftment and numbers of neutrophils and platelets in the blood compared with transplantation of PBMCs from donors pretreated with G-CSF. Next steps could include optimizing the engraftability of the HSCs...